Document Type : Research Paper

Authors

University of Anbar –College of Medicine.

10.37652/juaps.2012.78440

Abstract

Prostate cancer is the most common non skin cancer in men. Screening for prostate cancer with prostate specific antigen (PSA) may help in decreasing morbidity and mortality of men.to assess the PSA level among Iraqi men in Al-Anbar governorate.Hundred and sixty two patients with prostate cancer as a study group and fifty apparently healthy subjects as a control group were included in this study from the period of 1st of June, 2007 to 1st of October, 2010. All the patients were well diagnosed clinically and by laboratory investigations by their physicians and they were on therapy. Blood samples were taken from both the study and control groups and tested for detection of PSA levels. All PSA measurements were performed in the laboratory using ELISA test. A significantly higher percentages of patients with prostate cancer had a PSA level of more than 4.0 ng/ml (79.6%) than those among apparently healthy subjects (16%)(p<0.05). Men from older age groups had higher percentage of PSA level of ≥ 4.0 ng/ml than in younger age groups. Men with older age group are more exposed to risk of prostate cancer and should be encouraged to participate in early detection studies to define personalized PSA screening that may diagnose prostate cancer at a curable point.

Keywords

Main Subjects

1-National  Cancer Institute Surveillance Epidemiology and End Results Program. (2006) Cancer Stat Fact Sheets- Cancer  of  Prostate..
2-Wang  MC, Valenzuela AL, Murphy GP, and Chu TM.1979 Purification of  a human prostate specific antigen. Invest Urol,  17:159-163.
3-Farwell WR, Linder JA, and Jha AK. ( 2007); Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med., 167:2497-2502.
 4-Welch HC, Schwartz LM and Woloshin S. ( 2005);  Prostate specific antigen levels in the United States : implications of various definitions for abnormal. J  Natl Cancer Inst.    97:1132-1137.
5- Thomoson IM  and Ankerst DP. (2007);  Prostate- specific  antigen in the early detection of prostate cancer. Can Med Assoc J, 176(13)1853-1861
6-Jemal JA, Siege IR,Ward E, et al., (2007); Cancer statistics. Cancer J Clin,57:43-66.
7-Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, et al. (2004); Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate;59:311-318.
8-Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, et al. (2008); Prostate-cancer  mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol, 9:445-452.   
9-Welch HG and Albertsen PC. (2009);  Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening :1986-2005. Journal of the National Cancer Institute, 101(19):1325-1329.
10-Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al . (2004); Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. NEJM,351(14):1470-1477.
11-Catalona WJ , Smith DS, Ratliff TL, et al. (1991);  Measurement of prostate –specific antigen in serum as a screening test for prostate cancer  NEJM, 324:1156-1161
12-Smith DS., Humphery PA. , and  Catalona WJ. (1997); The early detection of prostate carcinoma with prostate specific antigen. Cancer, 80(9):1853-1856.
13-Nadler RB, Humphery P, Smith DS, Catalona WJand Ratliff TL. (1995);  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostatic specific antigen levels. J Urol,154(2):407-413.
14- Ries LAG.,  Melbert, D., Krapacho, M. et al. (2008); SEER  Cancer Statistics review. National Cancer Institute.